[특허]Platinum-catalyzed intravaginal rings

International Partnership for Microbicides

검색어에 아래의 연산자를 사용하시면 더 정확한 검색결과를 얻을 수 있습니다.
검색연산자

검색도움말
검색연산자	기능	검색시 예
()	우선순위가 가장 높은 연산자	예1) (나노 (기계 \| machine))
공백	두 개의 검색어(식)을 모두 포함하고 있는 문서 검색	예1) (나노 기계) 예2) 나노 장영실
\|	두 개의 검색어(식) 중 하나 이상 포함하고 있는 문서 검색	예1) (줄기세포 \| 면역) 예2) 줄기세포 \| 장영실
!	NOT 이후에 있는 검색어가 포함된 문서는 제외	예1) (황금 !백금) 예2) !image
*	검색어의 *란에 0개 이상의 임의의 문자가 포함된 문서 검색	예) semi*
""	따옴표 내의 구문과 완전히 일치하는 문서만 검색	예) "Transform and Quantization"

과학기술 지식인프라 ScienceON

연합인증

연합인증 가입 기관의 연구자들은 소속기관의 인증정보(ID와 암호)를 이용해 다른 대학, 연구기관, 서비스 공급자의 다양한 온라인 자원과 연구 데이터를 이용할 수 있습니다.

이는 여행자가 자국에서 발행 받은 여권으로 세계 각국을 자유롭게 여행할 수 있는 것과 같습니다.

연합인증으로 이용이 가능한 서비스는 NTIS, DataON, Edison, Kafe, Webinar 등이 있습니다.

한번의 인증절차만으로 연합인증 가입 서비스에 추가 로그인 없이 이용이 가능합니다.

다만, 연합인증을 위해서는 최초 1회만 인증 절차가 필요합니다. (회원이 아닐 경우 회원 가입이 필요합니다.)

연합인증 절차는 다음과 같습니다.

최초이용시에는
ScienceON에 로그인 → 연합인증 서비스 접속 → 로그인 (본인 확인 또는 회원가입) → 서비스 이용

그 이후에는
ScienceON 로그인 → 연합인증 서비스 접속 → 서비스 이용

연합인증을 활용하시면 KISTI가 제공하는 다양한 서비스를 편리하게 이용하실 수 있습니다.

특허 상세정보

MyON담기

내보내기 페이스북 공유 트위터 공유 카카오톡 공유

Platinum-catalyzed intravaginal rings

특허상세정보
국가/구분	United States(US) Patent 등록
국제특허분류(IPC7판)	A61F-006/14 A61K-009/00
미국특허분류(USC)	424/432;
출원번호	US-0276454 (2011-10-19)
등록번호	US-8580294 (2013-11-12)
발명자 / 주소	Malcolm, Karl Woolfson, David Romano, Joseph
출원인 / 주소	International Partnership for Microbicides
대리인 / 주소	McCarter & English LLP
인용정보	피인용 횟수 : 2 인용 특허 : 63

초록
▼

The present invention provides improved intravaginal drug delivery devices, i.e., intravaginal rings, useful for the prophylactic administration of an antimicrobial compound, e.g., Dapivirine, to a human. The intravaginal rings of the invention address previous stability issues by utilizing a platinum catalyst (e.g., in the form of a platinum-siloxane complex) for the cross-linking reaction. The vaginal rings surprisingly achieve relatively high and steady release rates in vivo with a matrix ring containing a relatively small loading dose. While the matrix rings of the present invention have in vivo the steady release rates associated with reservoir rings, they are easier and less expensive to manufacture. The present invention also provides methods of blocking DNA polymerization by an HIV reverse transcriptase enzyme, methods of preventing HIV infection in a female human, methods of treating HIV infection in a female human, and methods of preparing platinum-catalyzed intravaginal rings.

대표
청구항
▼

1. A platinum-catalyzed intravaginal ring comprising dapivirine, wherein between about 1 mg and about 3 mg of dapivirine is released in vitro from said ring during an initial 24 hour period of release. 2. The platinum-catalyzed intravaginal ring of claim 1, wherein between about 100 and about 500 micrograms of dapivirine is released in vitro each day for 21 days after an initial 7 day period of release. 3. The platinum-catalyzed intravaginal ring of claim 1, wherein use of the ring in vivo results in a steady level of between about 5 micrograms and about 300 micrograms of dapivirine per gram of vaginal fluid for 24 days after an initial 3 day period of use. 4. The platinum-catalyzed intravaginal ring of claim 1, wherein the intravaginal ring is a matrix-type ring. 5. The platinum-catalyzed intravaginal ring of claim 1, wherein the intravaginal ring comprises a silicone polymer. 6. The platinum-catalyzed intravaginal ring of claim 1, wherein dapivirine is homogenously dispersed throughout the ring. 7. The platinum-catalyzed intravaginal ring of claim 1, wherein dapivirine is present in the ring in a therapeutically effective amount. 8. The platinum-catalyzed intravaginal ring of claim 1, wherein dapivirine is present in the ring in a prophylactically effective amount. 9. The platinum-catalyzed intravaginal ring of claim 1, wherein about 10 to about 30 mg of dapivirine is present in the ring. 10. The platinum-catalyzed intravaginal ring of claim 1, wherein about 20 to about 30 mg of dapivirine is present in the ring. 11. The platinum-catalyzed intravaginal ring of claim 1, wherein about 10 to about 800 mg of dapivirine is present in the ring. 12. The platinum-catalyzed intravaginal ring of claim 1, wherein about 25 mg of dapivirine is present in the ring. 13. The platinum-catalyzed intravaginal ring of claim 1, wherein dapivirine release rates are stable following 3 months of storage. 14. The platinum-catalyzed intravaginal ring of claim 1, wherein dapivirine release rates are stable following 6 months of storage. 15. The platinum-catalyzed intravaginal ring of claim 1, wherein dapivirine release rates are stable following 12 months of storage. 16. The platinum-catalyzed intravaginal ring of claim 1, wherein dapivirine release rates are stable following 36 months of storage. 17. The platinum-catalyzed intravaginal ring of claim 1, wherein no crystalline deposits of dapivirine are formed on the surface of the ring. 18. The platinum-catalyzed intravaginal ring of claim 1, wherein the ring does not contain alcohol by-products. 19. The platinum-catalyzed intravaginal ring of claim 18, wherein the ring does not contain propanol by-products. 20. The platinum-catalyzed intravaginal ring of claim 1, wherein the intravaginal ring has an outer diameter of 56 mm. 21. The platinum-catalyzed intravaginal ring of claim 1, wherein the intravaginal ring has a cross-sectional diameter of 7.6 mm. 22. A platinum-catalyzed intravaginal ring comprising dapivirine, wherein said ring is a matrix-type ring. 23. The platinum-catalyzed intravaginal ring of claim 22, wherein between about 1 mg and about 3 mg of dapivirine is released in vitro from said ring during an initial 24 hour period of release. 24. The platinum-catalyzed intravaginal ring of claim 22, wherein between about 100 micrograms and about 500 micrograms of dapivirine is released in vitro each day for 21 days after an initial 7 day period of release. 25. The platinum-catalyzed intravaginal ring of claim 22, wherein use of the ring in vivo results in a steady level of between about 5 micrograms and about 300 micrograms of dapivirine per gram of vaginal fluid for 24 days after an initial 3 day period of use. 26. The platinum-catalyzed intravaginal ring of claim 22, wherein the intravaginal ring comprises a silicone polymer. 27. The platinum-catalyzed intravaginal ring of claim 22, wherein the dapivirine is homogenously dispersed throughout the ring. 28. The platinum-catalyzed intravaginal ring of claim 22, wherein the dapivirine is present in the ring in a therapeutically effective amount. 29. The platinum-catalyzed intravaginal ring of claim 22, wherein the dapivirine is present in the ring in a prophylactically effective amount. 30. The platinum-catalyzed intravaginal ring of claim 22, wherein about 10 to about 30 mg of the dapivirine is present in the ring. 31. The platinum-catalyzed intravaginal ring of claim 22, wherein about 20 to about 30 mg of the dapivirine is present in the ring. 32. The platinum-catalyzed intravaginal ring of claim 22, wherein about 10 to about 800 mg of the dapivirine is present in the ring. 33. The platinum-catalyzed intravaginal ring of claim 22, wherein about 25 mg of the dapivirine is present in the ring. 34. The platinum-catalyzed intravaginal ring of claim 22, wherein dapivirine release rates are stable following 3 months of storage. 35. The platinum-catalyzed intravaginal ring of claim 22, wherein dapivirine release rates are stable following 6 months of storage. 36. The platinum-catalyzed intravaginal ring of claim 22, wherein dapivirine release rates are stable following 12 months of storage. 37. The platinum-catalyzed intravaginal ring of claim 22, wherein dapivirine release rates are stable following 36 months of storage. 38. The platinum-catalyzed intravaginal ring of claim 22, wherein no crystalline deposits of dapivirine are formed on the surface of the ring. 39. The platinum-catalyzed intravaginal ring of claim 22, wherein the ring does not comprise alcohol by-products. 40. The platinum-catalyzed intravaginal ring of claim 39, wherein the ring does not contain propanol by-products. 41. The platinum-catalyzed intravaginal ring of claim 22, wherein the intravaginal ring has an outer diameter of 56 mm. 42. The platinum-catalyzed intravaginal ring of claim 22, wherein the intravaginal ring has a cross-sectional diameter of 7.6 mm. 43. A platinum-catalyzed intravaginal ring comprising dapivirine, wherein between about 5 micrograms and about 300 micrograms of dapivirine are released in vivo from said ring per gram of vaginal fluid for 24 days after an initial 3 day period of use. 44. The platinum-catalyzed intravaginal ring of claim 43, wherein the intravaginal ring comprises a silicone polymer. 45. The platinum-catalyzed intravaginal ring of claim 43, wherein dapivirine is homogenously dispersed throughout the ring. 46. The platinum-catalyzed intravaginal ring of claim 43, wherein dapivirine is present in the ring in a therapeutically effective amount. 47. The platinum-catalyzed intravaginal ring of claim 43, wherein dapivirine is present in the ring in a prophylactically effective amount. 48. The platinum-catalyzed intravaginal ring of claim 43, wherein about 10 to about 30 mg of dapivirine is present in the ring. 49. The platinum-catalyzed intravaginal ring of claim 43, wherein about 20 to about 30 mg of dapivirine is present in the ring. 50. The platinum-catalyzed intravaginal ring of claim 43, wherein about 10 to about 800 mg of dapivirine is present in the ring. 51. The platinum-catalyzed intravaginal ring of claim 43, wherein about 25 mg of dapivirine is present in the ring. 52. The platinum-catalyzed intravaginal ring of claim 43, wherein dapivirine release rates are stable following 3 months of storage. 53. The platinum-catalyzed intravaginal ring of claim 43, wherein dapivirine release rates are stable following 6 months of storage. 54. The platinum-catalyzed intravaginal ring of claim 43, wherein dapivirine release rates are stable following 12 months of storage. 55. The platinum-catalyzed intravaginal ring of claim 43, wherein dapivirine release rates are stable following 36 months of storage. 56. The platinum-catalyzed intravaginal ring of claim 43, wherein no crystalline deposits of dapivirine are formed on the surface of the ring. 57. The platinum-catalyzed intravaginal ring of claim 43, wherein the ring does not comprise alcohol by-products. 58. The platinum-catalyzed intravaginal ring of claim 57, wherein the ring does not contain propanol by-products. 59. The platinum-catalyzed intravaginal ring of claim 43, wherein the intravaginal ring has an outer diameter of 56 mm. 60. The platinum-catalyzed intravaginal ring of claim 43, wherein the intravaginal ring has a cross-sectional diameter of 7.6 mm. 61. The platinum-catalyzed intravaginal ring of claim 43, wherein between about 10 micrograms and about 100 micrograms of dapivirine are released in vivo from said ring per gram of vaginal fluid for 24 days after an initial 3 day period of use. 62. The platinum-catalyzed intravaginal ring of claim 61, wherein between about 20 micrograms and about 80 micrograms of dapivirine are released in vivo from said ring per gram of vaginal fluid for 24 days after an initial 3 day period of use. 63. A method of blocking DNA polymerization by an HIV reverse transcriptase enzyme in a female human, comprising the step of inserting the intravaginal ring of claim 1, claim 22 or claim 43 into the vagina of the female human. 64. A method of decreasing the likelihood that a female human will develop HIV, comprising the step of inserting the intravaginal ring of claim 1, claim 22 or claim 43 into the vagina of the female human compared to a female human who does not have the intravaginal insert ring. 65. A method of treating HIV infection in a female human, comprising the step of inserting the intravaginal ring of claim 1, claim 22 or claim 43 into the vagina of the female human.

이 특허에 인용된 특허 (63)

이 특허를 인용한 특허 피인용횟수: 2

IPC 상위 출원인

내보내기

상세정보
내보내기 구분	파일저장 인쇄 메일전송
구성항목	관리번호, 국가코드, 자료구분, 상태, 출원번호, 출원일자, 공개번호, 공개일자, 등록번호, 등록일자, 발명명칭(한글), 발명명칭(영문), 출원인(한글), 출원인(영문), 출원인코드, 대표IPC 관리번호, 국가코드, 자료구분, 상태, 출원번호, 출원일자, 공개번호, 공개일자, 공고번호, 공고일자, 등록번호, 등록일자, 발명명칭(한글), 발명명칭(영문), 출원인(한글), 출원인(영문), 출원인코드, 대표출원인, 출원인국적, 출원인주소, 발명자, 발명자E, 발명자코드, 발명자주소, 발명자 우편번호, 발명자국적, 대표IPC, IPC코드, 요약, 미국특허분류, 대리인주소, 대리인코드, 대리인(한글), 대리인(영문), 국제공개일자, 국제공개번호, 국제출원일자, 국제출원번호, 우선권, 우선권주장일, 우선권국가, 우선권출원번호, 원출원일자, 원출원번호, 지정국, Citing Patents, Cited Patents
저장형식	Text(ASCII format) Excel format PIAS분석(.xls)
메일정보	받는사람 (필수) @ 보내는사람 (선택) @ 제목 내용 KISTI 검색결과 이메일 서비스
안내	> 총 건의 자료가 검색되었습니다. > 다운받으실 자료의 인덱스를 입력하세요. (1-10,000) > 검색결과의 순서대로 최대 10,000건 까지 다운로드가 가능합니다. > 데이타가 많을 경우 속도가 느려질 수 있습니다.(최대 2~3분 소요) > 다운로드 파일은 UTF-8 형태로 저장됩니다. 파일의 내용이 제대로 보이지 않을실 때는 웹브라우저 상단의 보기 -> 인코딩 -> 자동선택 여부를 확인하십시오 > ~ > Text(ASCII format) Excel format

과학기술 지식인프라 ScienceON

ScienceON Chatbot

연합인증

특허 상세정보

Platinum-catalyzed intravaginal rings

초록
▼

대표
청구항
▼

이 특허에 인용된 특허 (63)

이 특허를 인용한 특허 피인용횟수: 2

IPC 상위 출원인

과제정보

상세정보조회

원문조회

IPC 상세정보(version : 201201)

연구과제 성과물(0)

참여연구원의 다른 문헌(0)

처리중입니다.

잠시만 기다려주세요.

ScienceON Chatbot

연합인증

특허 상세정보

Platinum-catalyzed intravaginal rings

초록 ▼

대표청구항 ▼

이 특허에 인용된 특허 (63)

이 특허를 인용한 특허 피인용횟수: 2

IPC 상위 출원인

과제정보

상세정보조회

원문조회

IPC 상세정보(version : 201201)

연구과제 성과물(0)

참여연구원의 다른 문헌(0)

처리중입니다.

잠시만 기다려주세요.

초록
▼

대표
청구항
▼